Who's the next Dendreon?

One popular new game in biotech investment circles is guessing the cancer vaccine developer that is most likely to follow in the footsteps of Dendreon (NASDAQ: DNDN), which braved some considerable challenges to bring Provenge to the market. But Trista Morrison at BNET dashes the fevered speculation with a bucket of cold water, noting that the road to Provenge's approval was littered with the burned wreckage of failed rivals. This is an extremely complex field that didn't get any easier to work in now that Provenge is coming to the market. And the second approval will require long years of development work. Report

Suggested Articles

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.